LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
STTK
Shattuck Labs, Inc.
There isn't enough reported data to score STTK yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
STTK Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
STTK's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
STTK PE Valuation
STTK has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
STTK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| -- | |
| Limited | |
| Low |
Analysts expect STTK's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over STTK on earnings quality, reporting a profit while its opponent remains loss making.
STTK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.56 | +$0.46 |
| Q2 2026 | -$0.56 | +$0.65 |
| Q1 2026 | -$0.68 | +$0.71 |
| Q4 2025 | -$0.82 | +$0.67 |
| Q3 2025 | -$1.02 | +$0.51 |
| Q2 2025 | -$1.21 | +$0.64 |
| Q1 2025 | -$1.39 | +$0.54 |
| Q4 2024 | -$1.49 | +$0.56 |
STTK is still losing money, but far less than before: $0.56 per share over the past year, against $2.43 at its worst in late 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over STTK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
STTK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $1M | -67% |
| Q3 2024 | $3M | +337% |
| Q2 2024 | $1.6M | +705% |
| Q1 2024 | $1.1M | +1856% |
| Q4 2023 | $714K | +83% |
| Q3 2023 | $686K | +224% |
| Q2 2023 | $200K | +300% |
| Q4 2022 | $390K | -99% |
STTK's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2025 | -1072% | -474 points |
| Q3 2024 | -598% | +3571 points |
| Q2 2024 | -1427% | +9946 points |
| Q1 2024 | -1798% | +36204 points |
| Q4 2023 | -2654% | +4083 points |
| Q3 2023 | -4169% | +7732 points |
| Q2 2023 | -11374% | +43943 points |
| Q1 2023 | -38002% | N/A |
STTK's operating margin was −1072% last quarter, up 1583 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with STTK at up 29%.
STTK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$17.5M | -$8.5M |
| Q1 2026 | -$13.4M | -$1.4M |
| Q4 2025 | -$8.5M | +$8.9M |
| Q3 2025 | -$9M | +$7.1M |
| Q1 2025 | -$12M | +$4.1M |
| Q4 2024 | -$17.4M | +$2.1M |
| Q3 2024 | -$16.1M | +$643K |
| Q2 2024 | -$10.9M | +$8M |
STTK has burned cash in almost every quarter: −$48M over the past year, against −$56M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over STTK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
STTK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +17.5M shares |
| 1 year | +154% | +78.8M shares |
| 3 years | +206% | +87.3M shares |
| 5 years | +210% | +87.9M shares |
| Available history | +579% | +111M shares |
STTK has 130M diluted shares, up 154% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
STTK Net Leverage
STTK's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
STTK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.6 | Neutral |
| Stochastic | 10.1 | Oversold |
STTK's weekly RSI is 40 (neutral) and its Stochastic is 10 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
STTK PE vs Healthcare Sector
STTK has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over STTK on trend strength, trading above more of its moving averages.
STTK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.58 | 14% below |
| 20 week MA | $6.43 | 25% below |
| 50 week MA | $5.68 | 15% below |
| 100 week MA | $3.48 | 38% above |
| 200 week MA | $3.90 | 23% above |
STTK has slipped below its 8-, 20- and 50-week averages, though it's still 23% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
STTK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.4 | $57.6 | +198% |
| 2021 | $57.6 | $8.90 | -85% |
| 2022 | $8.90 | $2.41 | -73% |
| 2023 | $2.41 | $7.13 | +196% |
| 2024 | $7.13 | $1.24 | -83% |
| 2025 | $1.24 | $3.35 | +170% |
| 2026 YTD | $3.35 | $4.81 | +44% |
STTK has the edge over LLY on returns for 2026, with the stronger performance.